Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Muhammad Mahdi Nashatizadeh"'
Autor:
Parham Habibzadeh, Zahra Tabatabaei, Soroor Inaloo, Muhammad Mahdi Nashatizadeh, Matthis Synofzik, Vahid Reza Ostovan, Mohammad Ali Faghihi
Publikováno v:
Frontiers in Genetics, Vol 11 (2020)
Autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS) is a rare neurodegenerative disorder caused by biallelic mutations in the SACS gene. Once thought to be limited to Charlevoix–Saguenay region of Quebec, recent evidence has indica
Externí odkaz:
https://doaj.org/article/887e7a48fec4409194598361a503174c
Autor:
Mohammad Ali Faghihi, Matthis Synofzik, Soroor Inaloo, Vahid Reza Ostovan, Parham Habibzadeh, Muhammad Mahdi Nashatizadeh, Zahra Tabatabaei
Publikováno v:
Frontiers in Genetics, Vol 11 (2020)
Frontiers in Genetics
Frontiers in genetics 11, 585136 (2020). doi:10.3389/fgene.2020.585136
Frontiers in Genetics
Frontiers in genetics 11, 585136 (2020). doi:10.3389/fgene.2020.585136
Autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS) is a rare neurodegenerative disorder caused by biallelic mutations in the SACS gene. Once thought to be limited to Charlevoix–Saguenay region of Quebec, recent evidence has indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cae4241dc96a57838bd29ca924d198e3
https://www.frontiersin.org/articles/10.3389/fgene.2020.585136/full
https://www.frontiersin.org/articles/10.3389/fgene.2020.585136/full
Autor:
Joan Thelen, Amanda Thuringer, Jared M. Bruce, Muhammad Mahdi Nashatizadeh, Sara Baker, Sharon G. Lynch
Publikováno v:
Multiple Sclerosis and Related Disorders. 49:102724
Background The Expanded Disability Status Scale (EDSS) measures disease progression in Multiple Sclerosis (MS). EDSS changes are assumed to be due to worsening MS-related disability. Strict interpretation of this premise may include some normal findi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5186036523480ebf4ed14cf1ee791784
https://doi.org/10.1016/j.msard.2020.102724
https://doi.org/10.1016/j.msard.2020.102724
Publikováno v:
Clinical Interventions in Aging. :179
Ropinirole prolonged release is a once-daily, 24-hour formulation of ropinirole, a non-ergot dopamine agonist. It is approved as monotherapy and as an adjunct to levodopa in the treatment of Parkinson’s disease (PD). Several potential advantages of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::354035d41f02bf70dcefb3caa929deb0
https://doi.org/10.2147/cia.s3358
https://doi.org/10.2147/cia.s3358